The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies. The competitive landscape for biosimilar ...
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences. Not all adalimumab biosimilars are created ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on comparative ...
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback